9780 Medical Center Drive
About GlycoMimetics, Inc.
GlycoMimetics is an oncology-focused biotechnology company. We are dedicated to improving the lives of patients by discovering, developing and commercializing novel, small-molecule glycomimetic product candidates.
Our management team consists of industry leaders with deep experience in the pharmaceutical/biotech industry.
Since our inception, we have developed a diversified product pipeline. Today, the company’s proprietary investigational drug for acute myeloid leukemia (AML) is being evaluated in two pivotal Phase 3 clinical trials.
231 articles with GlycoMimetics, Inc.
GlycoMimetics, Inc. announced that it will report its second quarter 2018 financial results on Thursday August 9, 2018, and will host a conference call and webcast on Friday, August 10, 2018, at 8:30 a.m. ET.
GlycoMimetics, Inc. announced that Chief Executive Officer Rachel King will provide a company overview at the Jefferies Annual Health Care Conference.
GlycoMimetics Announces NCI-Sponsored Pivotal Trial of GMI-1271 in Older, Newly Diagnosed AML Patients Fit for Intensive Chemotherapy
Third of three planned trials positions GlycoMimetics to address unmet needs across the AML spectrum
GlycoMimetics, Inc. reported its financial results for the first quarter ended March 31, 2018 and highlighted recent company achievements.
GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its first quarter 2018 financial results on Thursday, May 3, 2018, at 8:30 a.m. ET.
GlycoMimetics, Inc. announced the pricing of its underwritten public offering of 7,000,000 shares of its common stock at a price to the public of $17.00 per share.
GlycoMimetics, Inc. announced that it intends to offer and sell, subject to market conditions, 4,500,000 shares of its common stock in an underwritten public offering.
GlycoMimetics, Inc. announced that preclinical research suggesting the potential of two of its drug candidates, GMI-1271 and GMI-1359, as treatments for acute myeloid leukemia (AML), metastasis in osteosarcoma and other cancers will be shared via poster presentations at the AACR Annual Meeting 2018 in Chicago.
GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will present at four investor conferences during the month of March
The Phase 3 trial of rivipansel remains on track for completion during the second half of 2018.
GlycoMimetics, Inc. (NASDAQ: GLYC) announced today its design for a randomized, double-blind, placebo-controlled Phase 3 clinical trial to evaluate GMI-1271 in combination with MEC (Mitoxantrone, etoposide and Ara-C) or in combination with FAI (fludarabine, cytosine arabinoside and idarubicin) in individuals with relapsed/refractory acute myeloid leukemia (AML).
Discussion to focus on Phase 3 development plans for GMI-1271 in AML
GlycoMimetics Enters into Agreement with HOVON to Initiate Study Startup Activities for Planned Clinical Trial of GMI-1271 and Decitabine in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Unfit for Chemotherapy
GlycoMimetics, Inc. announced today that it has entered into an agreement with the Haemato Oncology Foundation for Adults in the Netherlands (HOVON) group to initiate clinical trial startup activities.
1/15/2018Many investors and analysts expect that the changes to the corporate tax code will lead to increased merger and acquisition activity in 2018.
The annual re-ranking of the NASDAQ Biotechnology Index will be effective prior to market upon on Monday, December 18, 2017.
GlycoMimetics defied a hematology biotech pitfall Tuesday, breaking out on strong cancer-drug data as shares of Global Blood Therapeutics and Spark Therapeutics trended in the opposite direction.
GlycoMimetics Reports Improvements in Median Overall Survival Versus Historical Matched Controls for Two AML Patient Subgroups in Phase I/II Trial for GMI-1271
This translational research provides important evidence that elucidates how treatment with GMI-1271 appears to be improving sensitivity to chemotherapy.
In an overall good year for pharma and biotech sectors, there have been some standouts.
As of September 30, 2017, GlycoMimetics had cash and cash equivalents of $112.9 million as compared to $40.0 million as of December 31, 2016.
GlycoMimetics announced today that it will host a conference call and webcast to provide a corporate update and report its third-quarter 2017 financial results on Wednesday, November 8, 2017, at 8:30 a.m. ET.